Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.52 +2.3%	$7.30	$5.90 ▼ $30.31	$536.49M	2.17	1.50 million shs	1.88 million shs
BHVN Biohaven	$13.81 -1.7%	$15.31	$13.04 ▼ $55.70	$1.41B	0.91	1.32 million shs	1.35 million shs
KNSA Kiniksa Pharmaceuticals International	$28.42 -2.1%	$27.90	$17.82 ▼ $30.69	$2.12B	0.05	559,497 shs	492,519 shs
RYTM Rhythm Pharmaceuticals	$88.63 -0.6%	$67.14	$40.61 ▼ $94.80	$5.64B	2.26	589,205 shs	667,966 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+2.31%	-4.45%	+1.08%	-15.88%	-73.63%
BHVN Biohaven	-1.67%	-2.66%	-4.83%	-34.57%	-61.63%
KNSA Kiniksa Pharmaceuticals International	-2.07%	-1.32%	-0.07%	+41.96%	+33.87%
RYTM Rhythm Pharmaceuticals	-0.64%	-0.58%	+42.97%	+49.64%	+78.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.8948 of 5 stars	4.3	4.0	0.0	1.9	2.5	1.3
BHVN Biohaven	3.2254 of 5 stars	4.5	1.0	0.0	2.3	2.5	0.6
KNSA Kiniksa Pharmaceuticals International	3.4298 of 5 stars	3.5	4.0	0.0	2.4	3.3	0.6
RYTM Rhythm Pharmaceuticals	3.1824 of 5 stars	2.5	1.0	4.3	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$20.29	169.81% Upside
BHVN Biohaven	3.07	Buy	$58.46	323.48% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.67	39.57% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	3.72% Upside

Current Analyst Ratings Breakdown

Latest ARVN, KNSA, BHVN, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.08	N/A	N/A	$8.17 per share	0.92
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.90	N/A	N/A	$6.60 per share	4.31
RYTM Rhythm Pharmaceuticals	$136.86M	41.20	N/A	N/A	$0.35 per share	253.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	113.68	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest ARVN, KNSA, BHVN, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	BHVN Biohaven	-$1.94	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.58	4.58
BHVN Biohaven	N/A	2.33	2.33
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BHVN Biohaven	88.78%
KNSA Kiniksa Pharmaceuticals International	53.95%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
BHVN Biohaven	16.00%
KNSA Kiniksa Pharmaceuticals International	53.48%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

ARVN, KNSA, BHVN, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $105.00

July 21 at 4:03 AM | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Cut to "Sell" at Wall Street Zen

July 21 at 3:11 AM | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street Zen

July 19 at 2:07 AM | marketbeat.com

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

July 18, 2025 | msn.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $105.00 Price Target at Canaccord Genuity Group

July 18, 2025 | marketbeat.com

Q2 Earnings Estimate for RYTM Issued By Leerink Partnrs

July 16, 2025 | marketbeat.com

Analysts Set Expectations for RYTM Q4 Earnings

July 15, 2025 | marketbeat.com

Q2 EPS Estimate for Rhythm Pharmaceuticals Lifted by Analyst

July 15, 2025 | americanbankingnews.com

Leo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 14, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $3,389,817.60 in Stock

July 14, 2025 | americanbankingnews.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 15,572 Shares of Stock

July 14, 2025 | americanbankingnews.com

Leerink Partnrs Issues Optimistic Outlook for RYTM Earnings

July 14, 2025 | marketbeat.com

Alps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 13, 2025 | marketbeat.com

Bank of America Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

Wells Fargo & Company Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

The Goldman Sachs Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 13, 2025 | americanbankingnews.com

Oppenheimer Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

July 13, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12, 2025 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - Nasdaq

July 12, 2025 | nasdaq.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of Stock

July 12, 2025 | insidertrades.com

Q2 Earnings Forecast for RYTM Issued By Leerink Partnrs

July 12, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, KNSA, BHVN, and RYTM Company Descriptions

Arvinas NASDAQ:ARVN

$7.52 +0.17 (+2.31%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$7.46 -0.06 (-0.81%)

As of 07:51 AM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Biohaven NYSE:BHVN

$13.80 -0.25 (-1.74%)

Closing price 07/21/2025 03:58 PM Eastern

Extended Trading

$14.08 +0.27 (+1.96%)

As of 07:25 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.42 -0.60 (-2.07%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$27.99 -0.43 (-1.51%)

As of 07/21/2025 05:38 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rhythm Pharmaceuticals NASDAQ:RYTM

$88.63 -0.57 (-0.64%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$88.64 +0.01 (+0.01%)

As of 07:05 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time